Skip to content
Subscriber Only
Business
Prognosis

Singapore Will Get First Claim to Any Successful Arcturus Vaccine

  • Effort comes as nations race to get supply of effective shots
  • Arcturus, Duke-NUS aim to create effective single-dose vaccine
Video player cover image
Covid-19 Vaccine May Require 2 Doses

Singapore sought out U.S. Covid-19 vaccine developer Arcturus Therapeutics Holdings Inc. and is funding its research in order to secure the first doses of any successful final product, in a reflection of the growing urgency in the race for immunization.

San Diego-based Arcturus, in a partnership with Duke-NUS Medical School, is now in the early stages of human testing with the goal of producing a single-shot vaccine to immunize the Southeast Asian country’s population, said Chief Executive Officer Joseph Payne.